High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.
This multicenter, open-label, randomized phase 3 trial evaluated the impact of dose-escalated radiotherapy (80 Gy) versus standard radiotherapy (70 Gy) on progression-free survival in 505 men with high-risk prostate…
Why it matters
The findings suggest that higher doses of radiotherapy may enhance progression-free survival in high-risk prostate cancer patients, which could influence treatment strategies and patient outcomes in this population.